AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04821258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MICODIGEST 2.0 supplement
Description: MICODIGEST is a nutraceutical which contains 9 different fungal extracts: Ganoderma lucidum, Agaricus blazei, Grifola frondosa, Hericium erinaceus, Cordyceps sinensis, Inonotus obliquus, Pleurotus ostreatus, Polyporus umbellatus y Lentinula edodes
Study NCT04821258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Placebo
Study NCT04078555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENERGI-F703 GEL
Description: The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size.
Study NCT04078555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ENERGI-F703 GEL matched vehicle
Description: The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size.
Study NCT06409065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Program
Description: Meditation and discussion sessions will be audio recorded
Study NCT05424016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 120 mg/d propranolol started in a progressive way (with control of Blood Pressure and heart rate during the consultations) neurosurgical consultation and an MRI every six months
Study NCT05424016 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: follow-up
Description: routine follow-up (neurosurgical consultation and an MRI every six months)
Study NCT05811624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention, including behavioral weight reduction program combined with pain neuroscience education and cognition-targeted exercise therapy.
Description: 14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will focus simultaneously on cognition-targeted exercise therapy and behavioral weight reduction. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful. The behavioral weight reduction program includes a lifestyle approach, with changes in diet, behavior, and a physical exercise weight loss program, all aiming for a caloric deficit of 500 to 700 kcal/day.
Study NCT06497595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wegovy (2.4 Mg Dose) + exercise & nutrition
Description: Participants will participate in a 26-week, tri-weekly, exercise program. One 45-minute exercise session will be provided via a virtual meeting platform each week and recorded. The participants will be asked to independently repeat each recorded session twice on separate, non-consecutive days of the week without supervision. The program will focus on progressive resistance exercises using body weight, a resistance band and various household items. A weekly follow-up call will be conducted to gather feedback and monitor adherence along with a personal exercise diary that each participant will fill out and bring to each on-site visit. Each exercise session will be performed in small groups and will be administered by a fitness specialist. In addition, participants will receive personal individualized nutritional counseling which will be administered every 2-4 weeks online via ZOOM. A certified dietitian will conduct all diet sessions.
Study NCT06497595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wegovy (2.4 Mg Dose) + usual care
Description: Participants will receive dietary guidance as customary among patients with type 2 diabetes (T2D) and obesity monitored in a diabetes clinic. Additionally, general recommendations for physical activity (PA) according to the medical guidelines for PA for T2D will be given. Guidelines recommend 150 minutes or more of moderate to vigorous-intensity aerobic activity per week, spread over at least 3 days/week, with no more than 2 consecutive days without activity, or engage in 75 minutes/week of vigorous-intensity or interval training (for more physically fit individuals). Incorporate 2-3 sessions/week of resistance exercise on nonconsecutive days, decrease sedentary behavior and add flexibility and balance training 2-3 times/week. Participants in the GHRG will be requested to fill out an exercise diary (report on unsupervised training days) and a 2-day food diary for periodic monitoring which they will bring with them to each on-site visit.
Study NCT06566144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The treatment to be used in the study is in accordance with the latest guidelines for chronic LBP \[George et al., 2021; Owen, et al., 2020\]. A warm-up will be performed by walking on a treadmill for 10 minutes, followed by 3 sets of 10 to 15 repetitions of exercise: bridge, cat, abdominal, straight leg raising, and oyster, and 3 sets of 30 to 60 seconds of each isometric exercise (front plank and side plank), where the therapist will assess the optimal amount of repetitions for each individual. The rest period between sets will be 40 seconds, and the rest period between exercises will be 1 minute. The total duration of the session will be 40 minutes \[Sipaviciene et al., 2020; Kim et al, 2020\].
Study NCT06566144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathy treatment
Description: The osteopathy treatment group (OTG) will receive the same standard treatment for low back pain as the STG, which will be applied twice a week and osteopathy treatment every 15 days for 8 weeks, totaling 4 sessions. The duration of the osteopathy sessions
Study NCT05154084 — intervention group
Intervention type: BEHAVIORAL
Intervention: Performance feedback and education
Description: Hospitals and surgeons will have an online interactive performance feedback dashboard provided to them along with educational components.
Study NCT05887102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACHA Program
Description: Pharmacists in this group will complete the 85-minutes web-based training, schedule and realize at least 2 telephone consultations with participating women in their pharmacy (in the first month and 4 months after randomization) using standardized consultation guides based on the principles of motivational interviewing and, if necessary, the evidence-based web sheets about strategies to cope with side effects and other AET-related concerns. Women in this group will have access to a web site that includes video capsules to inform women about AET, evidence-based web sheets describing strategies to cope with side effects and other AET-related concerns, testimonies of women who had breast cancer and an AET and a list of resources available for women.
Study NCT06565884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home radiofrequency skin treatment instrument
Description: Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.
Study NCT05184517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oph1
Description: 0.5% CsA ophthalmic formulation, twice daily for 4 days and once on the fifth day, one eye (right).
Study NCT05184517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restasis
Description: 0.05% CsA ophthalmic formulation twice daily for 4 days and once on the fifth day, one eye (right).
Study NCT06565884 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasonic coupler for medical purposes
Description: In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
Study NCT05499377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 2 HTP flavor conditions (tobacco-flavored HeatSticks or Fresh Menthol-flavored HeatSticks), with equal probability and provided with a supply of their condition specific HTP and asked to use it in place of their usual menthol cigarettes for the next week. Participants use their own brand menthol cigarettes and assigned HTP both at home (naturalistic use) and in the clinical laboratory (two visits/week).
Study NCT05499377 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco product administration and assessment
Description: Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 2 HTP flavor conditions (tobacco-flavored HeatSticks or Fresh Menthol-flavored HeatSticks), with equal probability and provided with a supply of their condition specific HTP and asked to use it in place of their usual menthol cigarettes for the next week. Participants use their own brand menthol cigarettes and assigned HTP both at home (naturalistic use) and in the clinical laboratory (two visits/week).
Study NCT04581226 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: All children will be studied in the supine position. LUS will be performed with the portable device MicroMax (Sonosite, Bothell, Washington, USA) using a linear probe of 6 to 12 MHz. All ultrasound scans will be performed by the same anesthetist, who has experience of more than 30 lung ultrasound scans in pediatric patients. Each hemithorax will be divided into six regions, using three longitudinal lines (parasternal, anterior and posterior axillary) and two axial lines (one above the diaphragm and the other 1 cm above the nipples)
Study NCT05277376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemotrizinol (6%)
Description: Active sunscreen ingredient (Broad spectrum UV-Filter)
Study NCT06462924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeepGad
Description: Using the pre-contrast and low-dose Contrast-Enhanced Magnetic Resonance (CE-MRI) images as input and the true full-dose CE-MRI images as the ground truth. the Cycle GAN deep network (DeepGad), was trained to reconstruct the full-dose CE-MRI images from low-dose CE-MRI images.
Study NCT05811624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy intervention, including pain neuroscience education and cognition-targeted exercise therapy alone.
Description: 14 weeks, 18 treatment sessions~This includes:~* 3 sessions of Pain Neuroscience Education during the first two weeks (of which the second one will be held online). The aim is to to reconceptualize pain, to increase pain coping skills and to convince the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.~* 15 sessions which will only focus on cognition-targeted exercise therapy. The aim of the exercise program is to confront the patient with movements and activities that are feared, avoided and/or painful.
Study NCT06319326 — intervention group
Intervention type: OTHER
Intervention: Evaluation of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding.
Description: This is an observation study involving measurement of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding. No intervention is given to study participants.
Study NCT04680390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care engagement practices
Description: The control arm will be standard-of-care, which is as-needed case management for justice-involved women. The goals of case management services are to reduce recidivism, mitigate behavioral challenges, strengthen public safety, and build self-sufficiency skills. Case managers refer clients to appropriate services in the community (e.g., housing, food).
Study NCT06271434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: THYROX (Atlantic krill oil
Description: The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA- 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.
Study NCT06271434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The control capsules will be made of olive oil of equal size and color.
Study NCT06316349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isolated Resistance Training Program
Description: The hip range of motion (ROM) will be fixed at 45 degrees due to the limitation imposed by the femoral insertion of the intra-aortic balloon pump in both lower limbs to allow for a 45-degree knee extension ROM. Four sets of 10 knee extension repetitions will be performed with a 90-second rest interval between sets. The intensity (resistive load) will be set at 60% of the baseline load, calculated using the one-repetition maximum (1RM) test and increased by 10% after every 5 interventions.
Study NCT06316349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: For NMES, two electrodes (area of 5 x 9 cm) will be positioned perpendicular to the muscles of the femoral quadriceps. The parameters of NMES will remain fixed throughout the study: pulsed, biphasic current, with a frequency of 35Hz, pulse width of 1000µs, on-time of 7 seconds (with 3 seconds of rise, 1 second of sustainment, and 3 seconds of descent), and off-time switched off. These settings allow the onset of NMES to be synchronous with the start and end of hip extension for simultaneous execution with resistance exercises and a total of 40 stimulations. The intensity will be gradually adjusted until evoked contractions of grade 4 to 5 (partial muscle recruitment and total muscle recruitment) or the maximum intensity tolerated by the patient is achieved.
Study NCT04680390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigators Addressing INtersectional Stigma to Improve HIV Prevention Among Criminal-Justice Involved Women
Description: kINSHIP is a peer-led navigator intervention to address intersectional stigma and improve PrEP treatment initiation and engagement for justice-involved women. The key components of the kINSHIP intervention are to: 1) increase social support; 2) increase self-efficacy in accessing PrEP services; 3) enhance access to healthcare services; 4) improve adaptive coping skills to manage experiences of intersectional stigma.
Study NCT06208670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercises
Description: PMI is among the non-pharmacological methods nurses can offer caregivers (Yılmaz et al., 2019). Health professionals, especially nurses, should evaluate all women of reproductive age in terms of PMS, plan educational interventions that will increase their awareness of the issue and enable them to develop appropriate coping strategies, support the planned educational interventions through written or visual materials, provide effective and quality counseling services, and aim to improve women's decreased quality of life (Abay \& Kaplan 2019; Aksoy Derya et al. 2019; Akmalı et al. 2020). Women can be advised to do relaxation exercises such as walking, running, swimming, and yoga regularly (at least 30 minutes a day) as they reduce stress by increasing endorphin levels and improve heart rate, lung capacity, and general health (Penedo \& Dahn, 2005; ACOG, 2015; Khajehei 2015).
Study NCT06217848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxenda
Description: Patients will receive subcutaneous injections of Saxenda 18 mg/3 mL Pen (liraglutide_obesity) starting at 0.6 mg qd. Increase by 0.6 mg qd at weekly intervals to 1.2 mg qd in week 2, 1.8 mg qd in week 3, 2.4 mg qd in week 4, 3.0 mg qd in week 5, and maintain for 8 weeks at a maximally tolerated dose within 3.0 mg starting in week 5. If the subject's response to treatment does not allow for escalation to the planned dose, subjects will inject an adaptive maximally tolerated dose within the planned dose at each cycle. Total duration of Saxenda treatment is 12 weeks.
Study NCT06166381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Antibacterial Agents
Description: Parenteral antibiotic (ceftriaxone) 1 g to be given in 3 doses, at induction of anesthesia, 12 hours postoperative, and 24 hours postoperative.
Study NCT06166381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Antibacterial Agents
Description: Parenteral antibiotic (ceftriaxone) 1 g to be given in 3 doses, at induction of anesthesia, 12 hours postoperative, and 24 hours postoperative.
Study NCT06166381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Antibacterial Agents plus Vancomycin pre-soaked graft
Description: in addition to the parenteral ceftriaxone intravenous injections, the ACL graft will be soaked in the vancomycin solution for 20 minutes when prepared outside the body of patient.
Study NCT05144100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with or without Neck Dissection
Description: An appropriate surgery as open, endoscopic, TLM, TORS or a combination with or without neck dissection e.g. levels dissected, sparing or sacrifice of the SCM, accessory nerve, etc as per patient disease and status will be performed
Study NCT05144100 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patients will receive IMRT with normal tissue sparing techniques (70Gy/35# or 66Gy/ 30#) along with concurrent weekly cisplatin. Weekly cisplatin will be administered during IMRT at a dose of 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36, and 43 for a total of upto 7 weekly doses, administered during the course of IMRT.
Study NCT05144100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin based chemotherpay
Description: Cisplatin (dose-40 mg/m2weekly,upto6-7cycles) cycle 1 will be administered within first 2 # of radiation. The rest of the cycles will be given weekly.
Study NCT06208670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Violent tendency Scale
Description: Violent tendency Scale
Study NCT05568628 — intervention group
Intervention type: DEVICE
Intervention: ultrasound
Description: screening of breast lesions by ultrasonography
Study NCT05327517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Patients receive esophagectomy or definitive chemoradiotherapy according to patient preference
Study NCT04724408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VieScope
Description: see above
Study NCT04724408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: see above
Study NCT05032482 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brainstem stimulation
Description: Study participants will self-administer \~19-minute treatments twice daily in the home setting over 24 weeks using a non-invasive brainstem modulation device. All participants will use the same treatment mode during the open label extension.
Study NCT05327517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Patients receive esophagectomy or definitive chemoradiotherapy according to patient preference
Study NCT05770817 — intervention group
Intervention type: OTHER
Intervention: N/A: SKyRoCKeT is an observational study
Description: None; this is an observational study
Study NCT05569239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836 480µg
Description: One single administration intramuscularly at Day 1.
Study NCT05569239 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: One single administration intramuscularly at Day 1.
Study NCT05917613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR/MPE)
Description: Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD)
Study NCT05335876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onasemnogene abeparvovec
Description: Onasemnogene abeparvovec is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the ytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec is administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
Study NCT06458543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Longidaza
Description: Bovhyaluronidase azoximer, vaginal suppositories 3000 IU, 1 suppository vaginally every other day, course of 10 days
Study NCT06458543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 500 mg
Description: Metronidazole, tablets 500 mg, 1 tablet 2 times a day, orally, course 7 days
Study NCT06458543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Description: Metronidazole, tablets 500 mg, 1 tablet 2 times a day, orally, course 7 days
Study NCT05701293 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular implantation of Renzan Stent
Description: Endovascular treatment of LEAD patients with Renzan Stent